ESPR
Esperion Therapeutics Inc
NASDAQ: ESPR · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$2.00
+4.71% today
Updated 2026-04-30
Market cap
$491.64M
P/E ratio
—
P/S ratio
1.22x
EPS (TTM)
$-0.11
Dividend yield
—
52W range
$1 – $4
Volume
6.1M
Esperion Therapeutics Inc (ESPR) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$2.00
12-Month target
—
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.1B | $0.1B | $0.1B | $0.3B | $0.4B | $0.5B | $0.5B | $0.6B | $0.6B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 12.12% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -5.63%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.